CD274 and neoplasm: Predictors of a response to these inhibitors include the expression of PD‐L1 in cancer or tumor‐associated immune cells (IC), tumor mutational burden (TMB), microsatellite instability (MSI) status, and the presence of tumor infiltrating lymphocytes.19, 20, 21 While immunotherapy has not yet been clinically validated for the treatment of salivary gland malignancies including SDC, several trials are underway.